Sharaf

PhD. Molecular pathology. Computational and Molecular Oncology. Postdoc @MSKCancerCenter

[ilyas sahin, MD @ilyassahinMD]

Newsweek/Statista’s World’s Best Specialized Hospitals 2027 oncology rankings are out.

[Segun Fatumo @SFatumo]

I am delighted to share that our book "Genomics in Africa" is officially published today by CRC Press, part of Taylor & Francis Group.

The book brings together the voices and experiences of researchers advancing human genetics and genomics across the continent.
@tchikowore1

[Sharaf @Sharaf501]

@YusufHassanW @Harvard NYC awaits. Sai ka shigo

[Segun Fatumo @SFatumo]

Delighted to see our paper published in @NatureComms

Largest GWAS of kidney function in Africa.

Lower frequency of APOL1 high risk variants in continental African populations

https://t.co/b8Z0YMFVgI

[Sharaf @Sharaf501]

@YusufHassanW A must-read article.

[Yusuf H. W. @YusufHassanW]

Penned my thoughts on the recent HMO outrage in Nigeria. Public frustration is understandable, but we must be careful not to throw away a policy that remains one of the strongest pathways to #UHC.

I’d love to hear your thoughts.

https://t.co/gBxhhkjGBy

[Stephen Martis @stephen_martis]

Excited to announce a new scientific initiative here at MSK, led by @bengrbm -- the Theory Group. As a part of this initiative, we're hiring fellows. Job description below and link at the end. 1/n

[Steve Moser @SteveMoser]

Why are recipes not laid out as Sankey diagrams?

[Ming "Tommy" Tang @tangming2005]

1/ Stop before you run that experiment.
Ask yourself:
Could public data already answer my question?
Because there’s a goldmine out there. 🧵

[Ming "Tommy" Tang @tangming2005]

🧵 You don’t know what you don’t know. And that’s exactly why you need people around you who do.
1/ I once met a postdoc who submitted 50 HPC jobs One by one.
No for-loop. No job array.
He just didn’t know better.

[Sharaf @Sharaf501]

@fsanchezvega @MSKCancerCenter @MSKEducation #aacr26

[Sharaf @Sharaf501]

https://t.co/OIb63MkzPA

[Sharaf @Sharaf501]

https://t.co/OIb63MkzPA

[Michael Morelli @morellifit]

A massive Nature study of 27,885 GLP-1 users just dropped some major news about Ozempic and tirzepatide.

Your DNA determines how much weight you lose and how bad the side effects hit.

1 in 3 people see minimal results, and now we know why: (1/9)

[Ming "Tommy" Tang @tangming2005]

1/ I used to panic every time a new *Seq method dropped.

ATAC-seq, CUT&Tag, scNOMe-seq, SHARE-seq... the list never ends. I tried to learn them all. I burned out.

Here's what I wish someone told me earlier.

[Banana Oncology @Banana_Oncology]

@wgibson This is unfortunately true. Fig S7

https://t.co/zGm3HZVBJ3

[Banana Oncology @Banana_Oncology]

Ok this figure is pretty intimidating...

[Denis Wirtz @deniswirtz]

Here is our updated database of grants for early careers researchers in all fields.

It goes way beyond traditional NIH and NSF funding opportunities. We list 428 types of grants.

Download it here: https://t.co/RGXGrdp2uf

[Mushtaq Bilal, PhD @MushtaqBilalPhD]

Zotero is the best citation/reference manager.

But many folks have a hard time starting out on it.

This step-by-step tutorial will teach you how to:

• Set up Zotero 8
• Build your library
• Take notes in Zotero
• Automate citations/references
• Change citations style

[Samuel Hume @DrSamuelBHume]

A brief history of p53-targeting cancer therapies

2003 — Gendicine, a p53 gene therapy, approved in China (but not elsewhere)

2012 — The first small molecule MDM2 inhibitor (RG7112, which works by preventing degradation of p53) enters trials, but did not progress to approval

2013 — Second-generation MDM2 inhibitor (Idasanutlin) reached phase 3, but failed and was dropped

2017 — A dual MDM2/MDMX inhibitor, ALRN-6924, enters trials; it has not since been approved

2020–2021 — A mutant p53 reactivator, Eprenetapopt, fails in phase 3

2023 — An MDM2 inhibitor, Milademetan, fails in phase 3

2024 — Promising phase 1 data for an MDM2 degrader

2026 — Rezatapopt phase 1 data: very promising early data, specific for the p53 Y220C mutation (present in 1% of all solid tumours)

[Samuel Hume @DrSamuelBHume]

How we're diagnosing obesity is changing

With the new method:

Someone with high BMI (but no excess body fat) does not have obesity

Someone with high BMI and excess body fat, but no signs/symptoms of obesity (like diabetes or shortness of breath) has preclinical obesity

Someone with high BMI, excess body fat and signs/symptoms has clinical obesity